Serum Lipids, Lipoproteins, Lipid Cardiovascular Indices and Peroxisome Proliferator-Activated Receptor-Gamma Among Non-Diabetic and Streptozotocin-Induced Diabetic Rats with Various Interventions

Abstract

Type 2 diabetes (T2DM) is a universal serious chronic disease with many complications. The oral antidiabetic drug of the thiazolidinediones (TZDs) including Pioglitazone) PGZ), and dietary supplements like chromium picolinate (Cr-PL) and chromium glucose tolerance factor (Cr-GTF) are mostly used as T2DM treatments. The study aims to determine the effects of Cr-PL, Cr-GTF, and PGZ, and their combination on serum peroxisome proliferator-activated receptors (PPAR-γ), and lipid profile including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG), as well as lipid atherogenic indices. A randomized design experiment using adult male Sprague-Dawley rats (220-300 g, n=63) was applied. Nine rats were selected randomly and assigned as a normal non-diabetic group, the other 54 rats were divided randomly into 6 main groups each with 9 rats, and each rat was injected intraperitoneally with streptozotocin (STZ) of dose = 40mg/kg of rat to induce T2DM. A dose of each of PGZ = 0.65 mg/kg (rat weight)/day, Cr-PL = 1 mg/kg (rat weight)/day, Cr-GTF = 1 mg/kg (rat weight)/day, and their combinations of (PGZ+Cr-PL) and (PGZ+Cr-GTF) were given to rats daily for 6 weeks according to each group of intervention. PPAR-γ serum levels were significantly higher in (PGZ+Cr-PL) group (P< 0.05) than in the Cr-PL group (244.5±0.6, 210.5±0.6, respectively).